Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop CDC-enhanced Daratumumab. For commercial partners interested in our CDC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Daratumumab is an immunoglobulin G1κ monoclonal antibody that specifically targets the CD38 antigen. CD38 is a transmembrane glycoprotein with many functions and is highly expressed in hematological malignancies, including multiple myeloma tumors. CD38 can regulate receptor-mediated adhesion, signaling, and cyclase and hydrolase activity. Daratumumab inhibits tumor cell growth and induces broad-spectrum apoptosis by binding to CD38 in a variety of mechanisms: Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and immune-dependent cell phagocytosis Lead tumor cell lysis.
Multiple Myeloma (MM)
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.